CUMULATIVE INDEX 1992

Volume 10

February	THE RIGHT VENTRICLE, pages 1–196
May	THE ATHLETE'S HEART, pages 197–339
August	AMBULATORY ELECTROCARDIOGRAPHY, pages 341–559
November	CARDIAC PACING, pages 561–769

Note: Page numbers of article titles are in **boldface** type.

AAI pacing, after heart transplantation, 582
  bradycardia-tachycardia syndrome, 584
  complications and survival, 628
  defined, 594
  rate-responsive pacing, 626
  sinus node disease, 698–700
  timing cycle, 594–595
AAIR pacing, after heart transplantation, 582
  bradycardia-tachycardia syndrome, 584
  rate-responsive pacing, 626
  timing cycle, 595
Accelerated atrioventricular junctional rhythm, 363–364
Acceleration-type pacemakers. See under *Rate-responsive pacing*
Adaptation to training, cardiovascular. See *Cardiovascular adaptation to training*
Adaptive rate pacemakers. See *Rate-responsive pacing*
Afterload, increased, caused by pulmonary venous hypertension, 172
  right ventricular response to, 112–115
Aging, and heart rate variability, 509–510
Alveolar hypoventilation, in normal lungs, 120–122
Ambulatory electrocardiography, ambulatory radionuclide left ventricular function studies, **473–478**
  clinical use, 475–476
  new developments, 477–478
  silent myocardial ischemia, 476–477
  the VEST, 474–475
  bradyarrhythmias, **367–369**
  coronary artery disease and myocardial ischemia, **417–430**
  asymptomatic and symptomatic patients, 418–419, 420, 421
  drug therapy and silent ischemia, 426–428
  monitoring of silent ischemia, 422–423
  prognostic significance, 423–426
  stress testing and ambulatory electrocardiography, 425–426
  technical issues, 420, 422
  drug therapy for silent myocardial ischemia, **479–486**
  antiplatelet therapy, 482–483
  β-blockers, 480–481
  calcium antagonists, 481–482, 483
  current clinical trials, 484
  nitrates, 479–480
  recommendations, 485
  revascularization for silent ischemia, 483
exercise testing and AEM for evaluation of myocardial ischemia, **461–466**
frequency domain analysis of heart rate variability, **499–537**
  autonomic function, 506–508
  clinical applications, 508–526
  power spectrum of heart rate, 501–506
history, 462
indications, **551–554**
myocardial ischemia, **403–415**
  determinants, 403–404
  stable angina pectoris, 405–410
  variant angina pectoris, 410–411
postcoronary artery bypass graft, **431–438**
  transient ischemic episode changes, 433–434
  transient ST-segment changes, 434–436
postpercutaneous transluminal coronary angioplasty, **438–444**
  ischemic markers, 440
  ST-segment changes, 439–442
  summary, 442–444
  transient ischemic episode changes, 438–439
proarrhythmia, drug-induced, **397–401**
risk assessment for vascular surgery, **467–472**
  ambulatory monitoring, 469–471
  dipyridamole thallium scintigraphy, 469
  exercise treadmill testing, 467, 469
signal averaging electrocardiography, **539–549**
  applications, 539–544
  background, 539–544
  clinical utility, 547–548
  future directions, 548
  history and literature, 544–547
  limitations, 548
silent myocardial ischemia, **449–459**
  epidemiology, 450
  late proarrhythmia and, 457
  severe transmural ischemia, 452–454
  silent ischemia versus true ischemia, 449–450
  subendocardial ischemia, 454–456
  sudden cardiac death, **456–457**
  and sudden cardiac death, 456–457

Ambulatory electrocardiography *(Continued)*
supraventricular tachyarrhythmias, **361–364**
technology, **341–359**
clinical applications, 351–356
continuous 24- to 48-hour electrocardiography, 341–344
intermittent and noncontinuous electrocardiography, 344–347
special modifications, 348–350
surveillance electrocardiography, 347–348
time domain measurements of heart rate variability, **487–498**
compared with frequency domain analysis, 489–490
correlation of variables, 489
drugs and, 491
heart disease other than myocardial infarction, 494
indices, 492–494
long-term, 488–489
noncardiac diseases, 491
short-term, 487–488
stability of, 490–491
ventricular arrhythmia, evaluation of, **371–395**
ambulatory monitoring, 381–385
electrophysiologic testing, 385–389
exercise testing, 375–381
invasive versus noninvasive methods, 390
signal averaging electrocardiography, 371–375
Ambulatory radionuclide left ventricular function studies, **473–478**
clinical use, 475–476
components of the VEST, 474–475
development, 473–474
new developments, 477–478
silent myocardial ischemia detected by, 476–477
American College of Cardiology/American Heart Association, codes for pacing systems, 593–594
guidelines for pacing, 573
Amiodarone, 491, 526
Amyloidosis, in athletes, 314
Anabolic steroids, as cause of sudden death, 313
physiologic hypertrophy and, 230, 285
Anatomy and pathology of right ventricle, **1–21**, 70–75
pathology, 2–8
right-sided valvular heart disease, 8–17
Angina pectoris, resulting from myocardial ischemia, 403–404
stable, circadian rhythms, 408–410
endothelium-derived relaxant factor (EDRF), 408
myocardial ischemia in, 405–410
platelets in epicardial vessel vasomotion, 408
vasomotion of epicardial coronary arteries, 407
unstable, 411, 424–425
variant, 410–411
Angiocardiography, radionuclide. See *Radionuclide angiocardiography*
Angioplasty, transluminal. See *Percutaneous transluminal coronary angioplasty*
Anti-ischemic drugs, **479–486**
antiplatelet therapy, 482–483
β-blockers, 464, 465, 480–481, 489, 491, 521, 526
calcium antagonists, 465, 481–482, 483, 491, 521, 526
current clinical trials, 484
nitrates, 465, 479–480, 491
recommendations, 485
revascularization of silent myocardial ischemia, 483
summary of clinical trials, 484
Antianginal drugs, myocardial ischemia, 427–428
silent myocardial ischemia, 421–422, 426–427
Antiarrhythmic drugs. See also *Proarrhythmia, drug-induced*
ambulatory monitoring and selection of, 384–385
assessment by exercise test and ambulatory electrocardiography, 464–465, 552
catecholamines and, 379–380
electrophysiologic effects, 379
electrophysiologic testing and selection of, 388–389
and heart rate variability, 491, 521, 526
invasive versus noninvasive methods of selection, 390
signal averaging electrocardiography and selection of, 374–375
Antibiotic therapy of endocarditis, 143–146
Antibradyarrythmia pacing. See *Mode selection in antibradyarrhythmia pacing*
Anticholinergic drugs, and heart rate variability, 491
Antihypertensive drugs, and heart rate variability, 491
Antiplatelet therapy, 482–483
Aortic regurgitation, in athletes, 297
Aortic valve disease, in athletes, 297, 298, 315
Aortocoronary bypass surgery. See *Coronary artery bypass graft*
Aprinde, 457
Arrhythmias, 351–356. See also *Antiarrhythmic drugs; Proarrhythmia, drug-induced*
ambulatory monitoring, 381–385, 547
bradyarrhythmias, 367
drug selection, 374–375, 390
electrophysiologic testing, 385–389
evaluation by ambulatory electrocardiography, 351–356
exercise testing, 375–381
indicated by heart rate variability, 493–494
induced by exercise, 376–378
nonsustained ventricular tachyarrhythmia (NSVT), 376, 377, 382–384, 387–388
scheme for arrhythmogenesis, 372
signal averaging electrocardiography, 371–375
slow atrial rhythms, 367
slow ventricular rhythms, 367
subendocardial ischemia and, 454–456
supraventricular tachycardias, classification and mechanisms, 361–364
long-term electrocardiographic recordings, 364–367
Arrhythmias, in athletes, 301–302
bradycardias, 301
in hypertrophic cardiomyopathy, 307
potentially fatal ventricular arrhythmias, 301–302
tachycardias and atrial fibrillation, 301
Arrhythmogenic dysplasia. See *Dysplasia, arrhythmogenic*
Arteriovenous oxygen difference (AVO_2), 210, 212, 214, 263
Aspirin antiplatelet therapy, 482–483
Assist devices, right ventricular, as a bridge to transplantation, 190–191
in cases of pulmonary embolism, 191
clinical applications, 187–191
history, 185
specific devices, 187–188
in surgical treatment of right ventricular failure, **185–192**
Athlete's heart. See also *Hypertrophy, physiologic*
cardiac pacing indications, 576–577
cardiovascular adaptation to training, **257–266**
due to endurance training, 257–261
loss of adaptations after cessation of training, 261–265
in patients with coronary artery disease, 260–261

causes of sudden death, **303–317**
coronary artery anomalies, 309–312
coronary atherosclerosis, 305–306
hypertrophic cardiomyopathy, 306–309
idiopathic left ventricular hypertrophy, 309
implications for cardiac screening, 315
miscellaneous causes, 313–315
published reports of, 304–305
right ventricular dysplasia, 312–313
electrocardiogram in trained athletes, **295–302**
arrhythmias, 301–302
arrythmogenic right ventricular dysplasia, 298
cardiac trauma, 298
older athletes, 300–301
organic disease associated with sudden death, 297–298
physiologic adaptive changes and, 295–297
physiologic versus pathologic hypertrophy, 298–300
recognition of structural heart disease, 297
historical perspectives, **197–207**
anatomic findings, 199–200
electrocardiographic findings, 201–203
functions of athlete's heart, 203–206
radiologic findings, 200–201, 203
impact of different sports, **214–256**
cardiac function in athletes, 247, 250
cardiac structure, 241–247
dynamic aerobic sports, 242–245
dynamic anaerobic sports, 245–247
genetic endowment and environmental factors, 250–254
left ventricular function, 247, 250
static sports, 247, 248
isometric athletes, **281–294**
acute cardiovascular response, 281–282
left ventricular function, 285–286
maximal oxygen consumption, 282
peripheral adaptation to, 286–291
training effects, 282–285
left ventricular systolic and diastolic function, **227–240**
confounding factors, 228–230
diastolic mechanics, 235–237
structural alterations, 230–232
systolic mechanics, 232–235
ventricular versus myocardial mechanics, 227–228
morphologic consequences of training, **219–226**
changes due to training, 224
development of athlete's heart, 223–224
echocardiographic studies, 220–221
left ventricular cavity, 221
left ventricular mass, 223
left ventricular wall thickness, 221–223
physiologic versus pathologic hypertrophy, 224–225
outer limits of physiologic hypertrophy, **267–279**
criteria for differential diagnosis of hypertrophy, 272–275
diagnostic perspectives, 275
echocardiographic patterns in elite athletes, 270–272, 273
echocardiographic studies, 268–270, 274–278
historical perspectives, 267–268
physiologic consequences of training, **209–218**
dynamic exercise and, 209–212
effects of systematic training, 214–217
static exercise and, 212–214
preparticipation sports examination, **319–328**
cardiac examination, 326–327
further evaluation and restriction of activity, 327
low risk of cardiovascular complications and, 319–320
low risk of sudden death and, 320
normal variants in athletes, 321
problems with routine screening, 320–321
problems with routine stress testing, 324, 326
screening studies in young athletes, 321, 324
racial differences in, **329–333**
cardiac response to exercise, 331
left ventricular hypertrophy, 330–331
preparticipation screening, 331–332
pressure overload on left ventricle, 329–330
Athlete's heart syndrome, 199
Atrial arrhythmias, and cardiac pacing, **609–617**
atrial fibrillation and, 609–610
occurrence in patients with DDD pacemakers, 611–613
AV node ablation combined with pacing, 615–616
DDD pacemaker selection considerations, 613–615
pacing mode effects on, 611
in patients with pacemakers, 610
Atrial fibrillation, characteristics, 609–610
chronotropic assessment, 713–714
occurrence in patients with DDD pacemakers, 611–613
and tachycardia, 362–363
Atrial flutter, 362
Atrial septal defect, 99–101, 297
Atrial septostomy, in right ventricular failure, 186–187
Atrioventricular block, in athletes, pacing indications for, 576–577
criteria for pacemaker mode selection, 720
survival, high-grade AV block and effect of pacing modes, 695–698
in patients with permanent pacemakers, 695–700
untreated type I and type II AV block, 691–692
vagally mediated, pacing indications for, 575–576
Atrioventricular nodal tachycardia, 363
Atrioventricular node ablation, and pacemaker therapy, 615–616
Atrioventricular sequential pacing, 626–627. See also *AAI pacing; AAIR pacing*
dual-chamber pacing, 626–627
maintenance of AV synchrony, 580, 622
and patient survival, 696–697
timing of atrioventricular delay, 627
Atropine, and heart rate variability, 491
Autonomic control, and rate-responsive pacing, 620
Autonomic neuropathy, and heart rate variability, 511–512
AVO_2. See *Arteriovenous oxygen difference (AVO_2)*

Bacterial endocarditis. See *Endocarditis*
Ball sports, 247, 249
Balloon counterpulsation, in right ventricular failure, 187
Baroreceptor sensitivity (BRS), indicating heart rate variability, 492
Base rate behavior, in pacemakers, 601–602
atrial-based timing, 601–602
ventricular-based timing, 601
β-blockers, anti-ischemic effects, 464, 465
and heart rate variability, 489, 491, 521, 526
treatment of silent myocardial ischemia, 480–481
β-receptor agonists, for right ventricle dysfunction, in pulmonary disease, 127

Bifascicular block, and patient survival rates, with permanent pacemakers, 698
in untreated patients, 693, 695
Bigelow, Wilfred, and invention of pacemaker, 566, 568
Biosensors, types of, in rate-responsive pacing, 623–624
Black athletes. See *Racial differences in athlete's heart*
Blanking period, in pacemakers, 599–600
Blood flow, in athletes, 212, 216
Blood pressure, arterial blood pressure, during static exercise, 282
diastolic, during exercise, 212
pulmonary artery pressure, 212
racial differences, in response to exercise, 329–331
in static exercise, 287–289, 290
systolic, during exercise, 212
Body builders. See *Power athletes*
Body surface area of athletes, adjusting to normal values, 229, 242
Bradyarrhythmias, 367
Bradycardia. See also *Mode selection in antibradyarrhythmia pacing*
in athletes, 204, 261, 296
pacing indications for, 576–577
chronotropic assessment, 712–713
British Pacing and Electrophysiology Group, codes for pacing systems, 593–594
guidelines for pacing, 573

Calcium antagonists, anti-ischemic effects, 465
and heart rate variability, 491, 521, 526
treatment of silent myocardial ischemia, 481–482, 483
Callaghan, John C., and invention of pacemaker, 566
Carcinoid tumors of tricuspid valve, 10–11, 49
Cardiac Arrhythmia Suppression Trial (CAST), 400, 457, 553
Cardiac glycosides, and heart rate variability, 491, 521
Cardiac output. See also *Stroke volume*
cardiac reserve, 706
changes in, after cessation of training, 263–264
chronotropic assessment, 706
isometric exercise and, 212
and rate-responsive pacing, 619, 621–622
relation to oxygen consumption (VO_2), 210
systematic training effect, 214, 219–220
Cardiac pacing, acceleration versus vibration, in rate-responsive pacing, **635–658**
algorithms for pacing rate, 643–644
clinical results, 646–653
sensors and pacemaker-mediated tachycardias, 653–656
special features, 644–645
technical and functional characteristics, 636–643
adaptive-rate pacemakers, **671–690**
comparative studies of sensors, 685
mixed venous oxygen saturation, 684
mixed venous pH, 684
mixed venous temperature, 679–680
paced depolarization integral, 683–684
respiration sensing (transthoracic impedance), 675–679
right ventricular pressure (first derivative), 684
sensor combinations, 685–687
stroke volume and pre-ejection interval, 685
ventricular repolarization, 680–683
vibration and body motion, 671–675
ambulatory electrocardiographic evaluation, 348–350
and atrial arrhythmias, **609–617**
atrial fibrillation, 609–610
atrial fibrillation with DDD pacemakers, 611–613
AV node ablation, 615–616
considerations for DDD pacemaker selection, 613–615
in pacemaker patients, 610
pacing mode effects, 611
electrographic parameters as sensors in rate-responsive pacing, **659–669**
clinical studies with QT-sensing pacemakers, 660–661
future developments, 664–666
limitations of QT-sensing pacemakers, 661–663
new developments in QT-sensing pacemakers, 663–664
QT interval variability, 659–660
QT-sensing pacemakers compared with other sensors, 662–663
ventricular depolarization gradient, 666–667
exercise testing for chronotropic assessment, **705–717**
abnormal chronotropic function, 712–714
chronotropic incompetence, 707–708, 721
chronotropic response and hemodynamics, 706
exercise protocols, 709–710
goals of exercise testing, 707
history of chronotropic evaluation, 705–706
history of exercise testing, 705
limitations of exercise testing, 706–707
metabolic stress testing, 714–715
normal chronotropic response, 710–711
techniques of exercise testing, 708–709
invention and reinvention, **561–571**
cardiac resuscitation and, 567–569
conditions in 1925–1932, 562–565
reinvention in 1952, 565–569
technical opportunities and medical need, 564–565, 566–567
lead extraction, **735–748**
countertraction, 745–746
extraction techniques, 737–743
indications, 735–737
surgical extraction, 743–745
mode selection in antibradyarrhythmia pacing, **719–734**
algorithm for, 724–725
clinical and electrocardiographic criteria, 720–722
mode-selection model, 722–726
retrospective study results, 726, 729
pediatric cardiac pacing, **749–754**
implant techniques, 751–754
indications, 749
leads, 751
pacemaker considerations, 750–751
selection of pacing mode, 749–750
physiology of rate-responsive pacing, **619–633**
atrioventricular sequential pacing, 626–627
atrioventricular synchrony, 622
biosensors, 623–624
complications and survival, 627–629
hemodynamic measurements, 619–622
rate-adaptive pacing, 622–624
ventricular pacing, 624–626
in special and complex situations, **573–591**
cardiac transplantation, 580–583
cardiomyopathy, 577–579
carotid sinus syndrome, 574
coronary artery disease, 579–580
cough syncope, 575
deglutition (swallowing) syncope, 575
hypervagotonia, 575–577

interatrial conduction block, severe, 585–586
neurally mediated syncope, 574–575
paroxysmal supraventricular tachyarrhythmias, 583–585
sinus bradycardia and AV block in athletes, 576–577
vagally mediated atrioventricular block, 575–576
survival with permanent pacemakers, **691–703**
effects of various pacing modes, 695–700
improved survival using physiologic pacing modes, 700–701
untreated conduction disturbances, 691–695
timing cycles of permanent pacemakers, **593–608**
AAI, 594–595
atrioventricular interval, 599–600
base rate behavior, 601–602
DDD, 598
DDDR, 603–604
DDI, 597
DDIR, 597
DVI and DVIR, 595–597
refractory periods, 598–599
single-chamber rate-modulated pacing, 595
upper rate behavior, 602–603
upper rate behavior of DDDR pacemakers, 604–607
VDD and VDDR, 597–598
VVI pacing, 594
Cardiac volume. See *Volume loading*
Cardiomyopathy, dilated cardiomyopathy, 578–579
hypertrophic, as cause of sudden death in athletes, 298, 306–309, 331
nuclear imaging techniques, 34
pacing indications for, 577–579
Cardiopulmonary bypass assist device, weaning from, 188, 190
Cardiovascular adaptation to training, endurance exercise training, **257–266**
in healthy persons, 258–260
hemodynamic changes after cessation of training, 263–265
loss of adaptation after cessation of training, 261–265
in patients with coronary artery disease, 260–261
regression of left ventricular hypertrophy, 261–263
isometric exercise training, **281–294**
acute cardiovascular response, 281–282
blood lipid, glucose, and insulin changes, 290–291
cardiovascular training effects, 282–285
hemodynamic changes, caused by static exercise, 286–289
in patients with cardiovascular disease, 289–290
left ventricular function following, 285–286
maximal oxygen consumption and, 282
peripheral cardiovascular adaptation, 286–291
racial differences in adaptive changes, 329–330
shown on electrocardiograms, 295–297
Cardiovascular diseases, and heart rate variability, 512–516
indications for ambulatory electrocardiography, 552
Carotid sinus syndrome, pacing indications and modes of stimulation, 574
CAST (Cardiac Arrhythmia Suppression Trial) study, 400, 457, 553
Catecholamines, arrhythmogenesis, 376
electrophysiologic effects, 379
interaction with antiarrhythmic drugs, 380
Central command, defined, 282
Chronic obstructive pulmonary disease, nuclear imaging techniques, 31–33
resulting in right ventricle dysfunction, 115–118
Chronotropic assessment. See under *Exercise testing*
Circadian rhythms, and heart rate variability, 510–511
in transient myocardial ischemia, 408–410, 432–433, 463
Circus movement tachycardia, 364, 365
CLV (cycle length variability), 489, 492–493
Coarctation of aorta, in athletes, 297
Complete heart block, and survival of pacemaker patients, 692–693
Conduction block, severe interatrial, pacing indications for, 585–586
Congenital heart disease, affecting right ventricle, **91–110**
in athletes, 297–298
atrial septal defect, 99–101
as cause of endocarditis, 140
corrected transposition, 103–105
echocardiography, 49–50
Eisenmenger's syndrome, 101–103
Fontan operation, 105–106
nuclear imaging techniques, 34–35
pulmonary valve stenosis, 97–99
scars from repair of, as cause of tachycardia, 157–159
tetralogy of Fallot, 91–94, 157–159
transposition of great arteries, complete, 94–97
of tricuspid valve, 49
Congestive heart failure, heart rate variability and, 513, 516
nonsustained ventricular tachycardia and, 383
nuclear imaging techniques, 34
physiologic pacing in, 700
Continuous ambulatory 24- to 48-hour electrocardiography, 341–344
conventional tape systems, 342
solid-state analysis systems, 342–344
Contractility, in athlete's heart, 235, 258–259
Contractility of right ventricle, in pulmonary venous hypertension, 174–175
Cor pulmonale, acute, following pulmonary embolism, 124
in chronic obstructive pulmonary disease, 31
pathology, 2–4
Coronary artery, right, 70
Coronary artery anomalies, abnormal coronary ostia, 309–312
hypoplastic coronary arteries, 312
tunnel coronary arteries, 312
Coronary artery bypass graft, ambulatory electrocardiographic evaluation, 431–438
compared with drug therapy for silent ischemia, 483
compared with percutaneous transluminal coronary angioplasty, 442
graft patency rate, 435
incidental pacemaker lead extraction during, 745
ST-segment changes, 432–436
summary, 442–444
transient ischemic episodes and, 433–434
Coronary artery disease, **417–430**. See also *Myocardial ischemia, silent*
ambulatory electrocardiographic monitoring, 418, 420, 422–423
asymptomatic coronary artery disease, 418
cardiovascular adaptations to training in patients with, 260–261
as cause of sudden death in athletes, 297–298, 305–306, 319
drug therapy and myocardial ischemia, 426–428
inflammatory coronary artery aneurysms, 314–315

Coronary artery disease *(Continued)*
ischemia during ambulatory electrocardiography, 422–423
mechanisms of myocardial ischemia, 405–407
nuclear imaging of, 29–31
pacing indications for, 579–580
pathophysiology of myocardial ischemia, 407–410
patient selection for ambulatory electrocardiography, 423
prevalence of silent myocardial ischemia in, 418
prognostic significance of silent myocardial ischemia, 423–425
reduced blood flow triggering myocardial ischemia, 406
silent ischemia in, 419–420, 421
stress tests and ambulatory electrocardiography, 425–426
Coronary blood flow, exercise and, 212
Coronary heart disease, right ventricular infarction in, 4–6
Corrected transposition, congenital, 103–105
Cough syncope, pacing indications for, 575
Cross-talk, in pacemakers, 599
Cycle length variability (CLV), 489, 492–493
Cyclists. See also *Dynamic exercise*
cardiac structure in, 245, 246
left ventricular cavity size in, 221
left ventricular wall thickness in, 222, 223, 224

Dancers, left ventricular wall thickness in, 221–223, 283
DDD pacing, atrial fibrillation and, 611–613
atrial tachyarrhythmias and selection of, 613
cardiomyopathy, 577–579
compared with VVIR pacing, in rate-responsive pacing, 626–627
interatrial conduction block, 585–586
lower rate limit, 613
rate modulation, 613, 615
retriggerable atrial refractory period, 583–584
sinus node disease, 698–700
slow upper rate, 584
supraventricular tachycardia, 584–585
timing cycle, 598, 599
upper rate limit, 613
DDDR pacing, atrial-driven and sensor-dependent upper rate, 584
compared with DDD and VVIR pacing, 627
interatrial conduction block, 585–586
timing cycle, 603–604
upper rate behavior, 603–604
DDI or DDIR pacing, carotid sinus syndrome, 574
neurally-mediated syncope, 574–575
paroxysmal supraventricular tachyarrhythmias, 584
timing cycle, 597
Defibrillation, and cardiac pacing, 567
Deglutition (swallowing) syncope, pacing indications for, 575
Diabetes mellitus, and heart rate variability, 511–512
Diastolic blood pressure. See *Blood pressure*
Diastolic function, assessment of, 63
of left ventricle, 235–237, 250, 272
Digitalis glycosides, and heart rate variability, 491, 521, 526
Digoxin, and heart rate variability, 491, 526
for right ventricular dysfunction, in pulmonary disease, 126–127
Diltiazem, 464, 481, 483, 491, 526
Dipyridamole thallium scintigraphy, 469, 471

Doppler echocardiography. See *Echocardiography*
Drug use, intravenous, as cause of endocarditis, 140
Dual chamber pacing, after heart transplantation, 582–583
rate-responsive pacing, 626–627
Dual lead atrial pacing, after heart transplantation, 582
DVI and DVIR pacing, neurally-mediated syncope, 755
timing cycle, 595–597
Dynamic exercise, and cardiac structure of athletes in various sports, 242–247
ball sports, 247, 249
cyclists, 245, 246
dynamic aerobic sports, 242–245
dynamic anaerobic sports, 245, 247
long-distance runners, 242–244
static sports, 247, 248
swimmers, 243, 244–245
triathletes, 245, 246
cardiovascular adaptation to training, 257–261
combined with static exercise, 214–215, 222
compared with static exercise, 229–230, 281–282
defined, 209
genetic factors and athlete's heart, 250–253
loss of cardiovascular adaptation after cessation of training, 261–265
morphologic consequences of, 219–220, 230–232
normal values for left ventricle in various sports, 269
physiologic consequences of, 209–212
Dysplasia, arrhythmogenic, echocardiography, 55
pathology, 6–8
right ventricular, 298, 312–313
and right ventricular tachycardia, 152–155

Ebstein's anomaly, of tricuspid valve, 11–14, 49
Echocardiography, in rate-responsive pacing, 629–630
of right ventricular conditions, arrythmogenic dysplasia, 55
chamber volume estimation, 44–47
diagnostic techniques, **41–58**
endocarditis, 53
enhanced imaging techniques, 55
ischemia, 52
masses, 53–54
normal views, 41–44
pericardial disease, 54–55
pressure overload, 51–52
right ventricular infarction, 78–79
valvar disease and congenital anomalies, 49–50
volume overload, 48–49
in trained athletes, estimates of left ventricular mass, 223
morphologic changes, 220–221, 222
movement of athlete's heart wall at rest, 205
patterns of physiologic hypertrophy, in elite athletes, 270–272, 273
physiologic hypertrophy, of athlete's heart, 202–203, 237, 268–270, 274–278
Eisenmenger's syndrome, 101–103
Ejection fraction, for assessing systolic cardiac function, 116–117
nuclear imaging techniques, 27–29, 31–32
in pulmonary venous hypertension, 172, 174
Electrocardiogram, in trained athletes, **295–302**
arrhythmias, 301–302
arrythmogenic right ventricular dysplasia, 298
cardiac trauma, 298
older athletes, 300–301

organic disease associated with sudden death, 297–298
physiologic adaptive changes and, 295–297
physiologic versus pathologic hypertrophy, 298–300
recognition of structural heart disease, 297
studies of hypertrophy, 201–202, 274
Electrocardiography, of right ventricular infarction, 76–77
Electrophysiologic testing and ventricular tachyarrhythmias, 385–389
after myocardial infarction, 386
cardiomyopathy and nonsustained ventricular tachycardia, 388
prognosis of sudden death, 385–388
selection of antiarrhythmic drugs, 388–389
Enalapril, 526
Encainide, 457, 491
End-stage renal disease, and heart rate variability, 511–512
Endocarditis, arising from right-sided heart structures, **137–150**
bacterial adherence to endocardium, 139
clinical symptoms, 141–143
echocardiography, 53
etiology and therapy, **137–149**
incidence, 139
microbiology, 141
myocardial lesions, 137–138
pathogenesis, 138–139
pathology, 137–138
predisposing factors, 139–141
congenital heart disease, 140
immunodeficiency, 140
intravenous drug use, 140
permanent pacemakers, 140
prognosis, 147
pulmonary lesions, 138
therapy, 143–147
antibiotics, 143–146
heparin, 147
surgery, 146
transient bacteremia, 138–139
of tricuspid valve, 14–15
Endothelium-derived relaxant factor (EDRF), 408
Endurance sports. See *Dynamic exercise*
Esophageal electrocardiography, 350–351
Exercise, effect on right ventricle, in pulmonary venous hypertension, 175–177
Exercise testing, assessment of anti-ischemic therapy, 464–465
of athletes, problems with, 324, 326
for chronotropic assessment, **705–717**
abnormal chronotropic function, 712–714
chronotropic incompetence, 707–708, 721
chronotropic response and hemodynamics, 706
exercise protocols, 709–710
goals of exercise testing, 707
history of chronotropic evaluation, 705–706
history of exercise testing, 705
limitations of exercise testing, 706–707
metabolic stress testing, 714–715
normal chronotropic response, 710–711
techniques of exercise testing, 708–709
combined with ambulatory electrocardiography, 425–426, **461–466**
correlation with ambulatory electrocardiography, 462–464
evaluation of arrhythmias, 375–381
management of arrhythmias, 378–381
prevalence and prognostic importance of arrhythmias during, 376–378
risk assessment for peripheral vascular surgery, 467, 469

Fast Fourier transform analysis of heart power spectra, 501, 535–541
First-pass radionuclide angiocardiography. See *Radionuclide angiocardiography*
Flecainide, 399, 457, 491, 526
Fontan operation, for congenital heart disease, 103–105
Fourier analysis of heart power spectra, 501, 535–541
Frank-Starling mechanism, 204, 211, 234, 258, 297
Frequency domain analysis of heart rate variability. See under *Heart rate variability*

Gated equilibrium radionuclide angiocardiography. See *Radionuclide angiocardiography*
Gender differences, cardiac dimensions, 269
maximal oxygen consumption (VO_2), 210
response to systematic training, 215
Genetic factors in athlete's heart, in dynamic sports, 250–253
physiologic hypertrophy and, 230, 274
racial differences in athlete's heart, 329
in static sports, 253–254
Girls. See *Women*
Glucose and insulin responsiveness, in static exercise, 290–291

Heart assist devices. See *Assist devices, right ventricular*
Heart conduction system, abnormalities, 313
retrograde ventriculoatrial conduction, and pacemaker mode selection, 721
severe interatrial conduction block, pacing indications for, 585–586
survival of patients with permanent pacemakers, 691–695
Heart disease, structural, and heart rate variability, 512–513
Heart enlargement. See *Hypertrophy, pathologic; Hypertrophy, physiologic*
Heart failure. See *Right ventricular failure, assist devices and*
Heart rate, determination of resting heart rate, 210
effect of systematic training, 215–216, 219
and rate-responsive pacing, 620
in static exercise, 286, 289
Heart rate variability, ambulatory electrocardiographic evaluation, 353, 354, 553
baroreceptor sensitivity (BRS) as an indicator, 492
cycle length variability (CLV) as an indicator, 492–493
defined, 499
drug effects, 491
frequency domain analysis, **499–537**
aging, 509–510
applications of heart rate power spectrum, 508–526
autonomic function and power spectrum, 506–508
autonomic neuropathy, 511–512
cardiovascular disease, 512–516
circadian rhythm, 510–511
compared with time domain measurements, 489–490, 500, 506

Heart rate variability *(Continued)*
congestive heart failure, 513, 516
diabetes, 511
end-stage renal disease, 511–512
estimation of power spectra, 534–537
Fourier analysis, 501, 535–541
heart transplantation and allograft rejection, 516–517
high-frequency component, 506–508
hypertension, 512
low-frequency component, 508
pharmacologic studies, 521, 522
power spectrum analysis, 535–541
power spectrum of heart rate, 501–506
structural heart disease, 512–513
sudden cardiac death, 517, 520–521
summary, 526–528
indicating sudden death and malignant ventricular arrhythmias, 493–494
indices of variability, 492–494
in noncardiac diseases, 491
normal heart rate determinants, 499
risk stratification, 493–494
time domain measurements, **487–498**
compared with frequency domain analysis, 489–490, 500, 506
correlation of variables, 489
definitions, 489
heart diseases other than acute myocardial infarction, 491
long-term measurements, 488–489
short-term measurements, 487–488
stability, 490–491
Heart septum, hypertrophy of, caused by athletic training, 223
thickening of, caused by isometric exercise, 220, 285
Heart size and weight. See also *Hypertrophy, physiologic*
critical heart weight, 200
largest hearts ever discovered, 201
radiologic findings, 200–201, 203
Heart sounds, in athletes, 274, 327–328
Heart transplantation, and heart rate variability, 516–517
modes of pacing and, 582–583
pacing indications after, 580–583
Heart ventricle. See *Left ventricle; Right ventricular dysplasia*
Hemodynamics of right ventricle, **59–67**
anatomy, 61–62
blood supply, 61–62
diastolic function, 63
in disease states, 64–65
normal function, 59–63
pressure overload, 64–65
principles of function assessment, 62–63
in right ventricular infarction, 79
systolic function, 62–63
Henschen, S., 197, 199, 201, 203–204, 267
Heparin, in endocarditis, 147
History of cardiac pacing. See *Invention of cardiac pacing*
Holter electrocardiography. See *Ambulatory electrocardiography*
Hospitals, as centers of resuscitation, 568–569
HRV. See *Heart rate variability*
Hyman, Albert S., and invention of pacemaker, 563, 564–565
Hypertension, in black athletes, 329–331
and heart rate variability, 512
in static exercise, 290
Hypertrophic cardiomyopathy, as cause of sudden death in athletes, 298, 306–309, 331
Hypertrophy, concentric, in power athletes, 202–203, 285
Hypertrophy, pathologic, compared with physiologic hypertrophy, 197–198, 224–225, 298–300
idiopathic left ventricular hypertrophy, 309
symptoms of, 274
Hypertrophy, physiologic. See also *Athlete's heart; Left ventricle*
in ball sports, 247, 249
compared with pathologic hypertrophy, 197–198, 224–225, 298–300
defined, 227
in dynamic aerobic sports, 242–245, 285
in dynamic anaerobic sports, 245, 247
echocardiographic studies of, 202–203, 220–223, 237, 268–278
electrocardiographic studies of, 201–202, 274, 298–300
harmonious hypertrophy, 199–200
hemodynamic changes after cessation of training, 263–265
historical perspectives, 199–200
left ventricular diastolic function, 235–237, 250
left ventricular systolic function, **227–240**
adjustment for body size, 229
afterload, 232–233
confounding factors, 228–230
contractility, 235, 258–259
genetic and other factors, 230
preload, 233–235
quantification of exercise intensity, 228–229
structural alterations, 230–232
summary, 237
systolic mechanics, 232–235
types of exercise, 229–230
ventricular versus myocardial mechanics, 227–228
normal values for left ventricle in various sports, 269
outer limits and diagnosis of, **267–279**
criteria for differential diagnosis of hypertrophy, 272–275
diagnostic perspectives, 275
echocardiographic studies, 268–278
historical perspectives, 267–268
racial differences in, 329–331
radiologic studies, 200, 203
regression, after cessation of training, 261–263
regulatory cardiac enlargement, 199
right-sided hypertrophy, 199, 202
in static exercise, 247, 248, 282–286
in strength versus endurance athletes, 231
training effect, 224, 259–261
volume loading as cause of, 231–232
in women, 201, 259, 269
Hypervagotonia, pacing indications for, 575–577
cough syncope, 575
deglutition (swallowing) syncope, 575
vagally mediated atrioventricular block, 575–576
Hypoxic pulmonary vasoconstriction, 112

Idiopathic left ventricular hypertrophy, 309
Indications for ambulatory electrocardiography, **551–554**. See also *Risk assessment*
antiarrhythmic drug assessment, 552
heart rate variability, 553
implications for reimbursement, 553
myocardial ischemia evaluation, 553

symptoms of underlying cardiac disorder, 552
Infarction. See *Right ventricular infarction*
Insulin responsiveness, in static exercise, 290–291
Intermittent and noncontinuous ambulatory electrocardiography, 344–347
Interstitial lung disease, 118–120
Interventricular septum, in pulmonary venous hypertension, 167–168
Intracavitary electrocardiography, 351
Intravenous drug use, as cause of endocarditis, 140
Invention of cardiac pacing, **561–571**
cardiac resuscitation and, 567–569
conditions in 1925–1932, 562–565
reinvention in 1952, 565–569
technical opportunities and medical need, 564–565, 566–567
Ischemia. See *Myocardial ischemia*
Isoenzyme analysis, in right ventricular infarction, 77
Isometric exercise. See *Static exercise*

Joggers. See *Runners*

Kidney failure, and heart rate variability, 511–512

Laplace's law, 203, 219, 221, 232
Late potentials, defined, 540
signal averaging electrocardiography, 372, 373, 540–548
Lead extraction, **735–748**
countertraction, 745–746
extraction techniques, 737–743
intravascular countertraction, 739–743
traction, 737–739
indications, 735–737
surgical extraction, 743–745
cardiopulmonary bypass, 745
debridement of infected tissue, 745
limited surgical approach, 743–745
ventriculotomy, 744
Left bundle branch block. See *Bifascicular block, and patient survival rates*
Left ventricle. See also *Hypertrophy, physiologic*
diastolic function in athlete's heart, 235–237, 250, 272
following static exercise training, 285–286
function assessment, for pacemaker mode selection, 721
idiopathic left ventricular hypertrophy, 309
morphologic consequences of exercise, structural alterations, 230–232
ventricular cavity, 221, 272
ventricular mass, 223, 283–284
wall motion, 272
wall thickness, 220, 221–224, 260, 269–270
normal values for left ventricle in various sports, 269
racial differences in adaptive changes, 329–330
systolic function in athlete's heart, **227–240**, 247, 250
adjustment for body size, 229
afterload, 232–233
confounding factors, 228–30
contractility, 235, 258–259
genetic and other factors, 230
preload, 233–235
quantification of exercise intensity, 228–229
structural alterations, 230–232
systolic mechanics, 232–235
types of exercise, 229–230
ventricular versus myocardial mechanics, 227–228
Lidwell, Mark C., and invention of pacemaker, 561, 562–563, 564
Life expectancy of athletes, 198
Lipids, changes in, caused by exercise, 290–291
metabolic effect of systematic training, 216–217
Lung disease. See *Pulmonary disease*
Lung transplantation, and nuclear imaging, 35

Marfan's disease, as cause of sudden death in athletes, 298, 315
physical examination of athletes with, 326
Masses in right ventricle, echocardiography of, 53–54
Maximal oxygen consumption (VO_2), aging and, 215
changes in, after cessation of training, 263–264
effects of systematic training, 214–215
gender differences, 210
as index of heart enlargement, 201
in isometric exercise, 212–213, 214, 282, 284
as a measure of exercise performance, 210–211, 257–258, 295
Metoprolol, 464
Mitral valve disease, in rheumatic tricuspid valve disease, 10
Mitral valve prolapse, in athletes, 314
Mitral valve stenosis, 166
Mixed venous oxygen saturation sensing, in adaptive-rate pacemakers, 684
Mixed venous temperature sensing, in adaptive-rate pacemakers, 679–680
Mode selection in antibradyarrhythmia pacing, **719–734**
algorithm for, 724–725
clinical and electrocardiographic criteria, 720–722
distribution of patients by selection criteria, 726
frequency of mode recommendations, 729
mode-selection model, 722–726
paroxysmal supraventricular tachyarrhythmias, 583–585
retrospective study results, 726, 729
single-chamber, dual-chamber, and adaptive-rate mode usage, 728
worksheet for mode selection, 723
Murmurs. See *Heart sounds*
Myocardial blood flow, right ventricle, 115
Myocardial infarction. See *Right ventricular infarction*
Myocardial ischemia, ambulatory electrocardiography and exercise testing, **461–466**
assessment of anti-ischemic therapy, 464–465, 553
antianginal drug therapy, 427–428
as cause of right ventricular tachycardia, 160
circadian rhythms and, 408–410, 463
compared with silent ischemia, 449–450
coronary blood flow, 404, 406
damage caused by, 461
defined, 422
determinants, 403–404
diagnostic utility of ambulatory electrocardiography, 420–421
echocardiography, 52
endothelium-derived relaxant factor (EDRF), 408
ischemic markers during percutaneous transluminal coronary angioplasty, 440
mental stress as trigger mechanism, 406–407
myocardial oxygen demand, 404, 405–406
other conditions with transient ST-segment changes, 410

Myocardial ischemia *(Continued)*
pathophysiology of pain, 410
reduced by aortocoronary bypass surgery, 433–434
reduced by percutaneous transluminal coronary angioplasty, 438–439
restenosis after percutaneous transluminal coronary angioplasty, 440–441
in right ventricular hypertrophy, 6
ST-segment changes, 403, 409–411, 422–423, 449–450
stable angina pectoris, 405–410
stable coronary artery disease, 405–410
unstable angina pectoris, 411
validation during ambulatory electrocardiography, 422–423
variant angina pectoris, 410–411
vasomotion of epicardial coronary arteries, 407
Myocardial ischemia, silent, ambulatory monitoring for detection of, 418, 422–423
ambulatory radionuclide left ventricular function studies, **473–478**
compared with true ischemia, 449–450
drug therapy, 426–427, **479–486**
antiplatelet therapy, 482–483
β-blockers, 464, 465, 480–481
calcium antagonists, 465, 481–482, 483
current clinical trials, 484
nitrates, 465, 479–480
recommendations, 485
summary of clinical trials, 484
indicators for ambulatory monitoring, 423
in known coronary artery disease, 419–420, 421
myocardial dysfunction and, 473, 476–477
patient selection for ambulatory monitoring, 423, 462
prevalence, 417–418, 419
prognostic significance, 423–425
revascularization, 483
in stable angina pectoris, 405
and sudden cardiac death, **449–459**
causal mechanisms, 450–456
direct and indirect relationship between, 456–457
electrical instability and ischemia, 451
epidemiology, 450
ischemic cascade, 450
late proarrhythmia, 457
physiopathology of sudden death, 452
risk markers, 451
severe transmural and persistent ischemia, 452–453
subendocardial ischemia, 454–456
triggers and markers, 452
Myocarditis, in athletes, 314–315
Neurally mediated syncope, pacing indications for, 574–575
Nifedipine, 464, 481, 483
Nifedipine-GITS, 482
Nisoldipine, 464
Nitrates, anti-ischemic effects, 465
and heart rate variability, 491
treatment of silent myocardial ischemia, 479–480
Nonsustained ventricular tachyarrhythmia (NSVT), 376, 377, 382–384, 387–388
North American Society of Pacing and Electrophysiology and British Pacing and Electrophysiology Group, 593–594
Nuclear imaging techniques, for assessment of right ventricular function, **23–39**
chronic obstructive pulmonary disease, 31–33
congenital heart disease, 34–35
congestive heart failure and cardiomyopathy, 34
coronary artery disease, 29–31
first-pass radionuclide angiocardiography, 24–25
functional parameters and normal values, 27–29
gated equilibrium radionuclide angiocardiography, 25
gated first-pass study, 25–26
pulmonary hypertension and lung transplantation, 35
septic shock, 33–34
valvular disease, 34
ventricular interdependence studies, 35–37
Nuclear stethoscope, 473
Nylin index, 201

Obliterative pulmonary vascular diseases, 122–124
Obstructive lung disease. See *Chronic obstructive pulmonary disease*
Older athletes, 300–301, 326
Outflow tract tachycardia, 155–157
Oxygen consumption (VO_2). See *Maximal oxygen consumption (VO_2)*
Oxygen therapy, for pulmonary diseases, 124–126

Paced depolarization integral sensing, in adaptive-rate pacemakers, 683–684
Pacemaker lead extraction. See *Lead extraction*
Pacing. See *Cardiac pacing*
Paroxysmal supraventricular tachyarrhythmias. See *Tachycardia, supraventricular*
Pediatric cardiac pacing, **749–754**
implant techniques, 751–754
indications, 749
leads, 751
pacemaker considerations, 750–751
selection of pacing mode, 749–750
Percutaneous transluminal coronary angioplasty, ambulatory electrocardiographic evaluation, 438–442
changes in transient ischemic episodes, 438–439
compared with coronary artery bypass surgery, 442
ischemic markers during, 440
prognosis after surgery, 441–442
restenosis rate, 440–441
ST-segment changes, 440–442, 483
summary, 442–444
Pericardial disease, echocardiography of, 54–55
role in pulmonary venous hypertension, 167
Pericardiectomy, in right ventricular failure, 186–187
Peripheral vascular surgery, ambulatory electrocardiography for assessing, **467–472**
dipyridamole thallium scintigraphy, 469, 471
exercise treadmill testing for assessing, 467, 469
intraoperative and postoperative ambulatory monitoring, 471
major complication rates, 468
preoperative ambulatory monitoring, 470–471
Physical examination of athletes, **319–320**
cardiac examination, 326–327
heart sounds, 274
low risk of cardiovascular complications and, 319–320
low risk of sudden death and, 320
normal variants in athletes, 321
problems with routine screening, 320–321
problems with routine stress testing, 324, 326
racial differences in athletes, 331–332
recommendations for participation in sports, 327

screen studies in young athletes, 321, 324
strategies for cardiovascular screening, 319–320
Physiologic hypertrophy. See *Hypertrophy, physiologic*
Physiologic pacing, in congestive heart failure, 700
preventing stroke, 700–701
Physiology of rate-responsive pacing. See also *Rate-responsive pacing*
Plasma volume, in athletes, 260–261, 262–263, 264
Platelets, in epicardial vessel vasomotion, 408
Plethysmography, of athlete's heart, 206
Positive end-expiratory pressure ventilation, 33
Post-coronary artery bypass graft. See *Coronary artery bypass graft*
Post-percutaneous transluminal coronary angioplasty. See *Percutaneous transluminal coronary angioplasty*
Power athletes. See also *Static exercise*
cardiac structure, 247, 248
concentric hypertrophy in, 202–203, 285
left ventricular mass, 284
left ventricular thickness-to-dimension ratio, 231
left ventricular wall thickness, 222–223, 260, 283–285
maximal oxygen consumption, 284
Power spectrum of heart rate, 501–506
Preparticipation sports examination. See *Physical examination of athletes*
Pressor reflex, exercise, 288
Pressure overload, right ventricular, echocardiography, 51–52
hemodynamics, 64–65
Pressure volume measurements, nuclear imaging techniques, 28–29
Proarrhythmia, drug-induced, **397–401**
clinical correlation, 399–400
comparison of early and late proarrhythmia, 400–401
definition, 397–399
and heart rate variability, 526
late proarrhythmia, 400, 457
subtypes of early proarrhythmia, 399
Propafenone, 526
Propranolol, 464, 481, 483
Propafenone, 526
Propranolol, 464, 481, 483
Pulmonary arterial hypertension, 168–170
Pulmonary artery pressure, 212
Pulmonary disease, afterload, acute increases in, 112–115
alveolar hypoventilation, with normal lungs, 120–122
basic physiology, 111–115
β-receptor agonists, 127
chronic obstructive pulmonary disease, 115–118
nuclear imaging techniques, 31–33
pulmonary function during exercise, 117–118
resting right ventricular function, 116–117
right ventricular function during exercise, 117
cor pulmonale, acute, 124
digoxin therapy, 126–127
hypoxic pulmonary vasoconstriction, 112
interstitial lung disease, 118–120
myocardial blood flow, 115
normal function, 111–115
obliterative pulmonary vascular diseases, 122–124
oxygen therapy, 124–126
right ventricle in, **111–136**
as symptom of endocarditis, 138
theophylline therapy, 127
therapy, 124–130
vasodilators, 127–130
Pulmonary embolism, acute cor pulmonale following, 124
as cause of obliterative pulmonary vascular disease, 122–123
secondary to endocarditis, 138
support from cardiopulmonary bypass assist device, 191
Pulmonary hypertension. See also *Cor pulmonale; Pulmonary venous hypertension*
in chronic obstructive pulmonary disease, 31
echocardiographic findings, 51
nuclear imaging for assessment of, 35
obliterative pulmonary vascular diseases as cause of, 122–124
pulmonary arterial hypertension, 168–170
vasodilator therapy, 128–130
Pulmonary stenosis, in athletes, 297
Pulmonary system, effect of systematic training, 216
Pulmonary valve, anatomy, 1–2
endocarditis, 53
insufficiency, 17
Pulmonary valve stenosis, diagnosis and management, 97–99
echocardiography, 51
pathology, 17
Pulmonary vasoconstriction, hypoxic, 112
Pulmonary vein stenosis, 166
Pulmonary venous hypertension, afterload, increased, 172
biochemical factors, 166–167
clinical findings, 175
drug therapy, 178
ejection fraction and right ventricular function, 172–174
etiologies, 165–166
exercise, effect of, 175–177
geometry of right ventricle and, 170–171
hemodynamics, 172
interventricular septum and, 167–168
left atrial etiology, 166
left ventricular failure as cause of, 165–166
pathophysiology, 166–170
pericardial influence, 167
prognosis for right ventricular performance, 178–180
pulmonary arterial hypertension as cause of, 168–170
right ventricle in disorders causing, **165–184**
right ventricular contractility, 174–175
right ventricular response, 170–177
structural adaptation of right ventricle, 171–172
therapy, 177–178

QT interval, evaluation by ambulatory electrocardiography, 353–354
QT-sensing pacemakers. See under *Rate-responsive pacing*

Racial differences in athlete's heart, **329–333**
cardiac response to exercise, 331
hypertension in black athletes, 329–331
left ventricular hypertrophy, 330–331
preparticipation screening, 331–332
pressure overload on left ventricle, 329–330
Radiographic studies of heart size in athletes, 200–201, 203
Radionuclide angiocardiography, first-pass, 24–25
gated equilibrium, 25
gated first-pass study, 25–26
of right ventricular infarction, 77

Radionuclide left ventricular function studies. See *Ambulatory radionuclide left ventricular function studies*
Rate-responsive pacing, acceleration versus vibration, **635–658**
algorithms for controlling pacing rate, 643–644
clinical results with accelerometers, 649–653
clinical results with vibrational sensors, 646–649
comparative technical analysis, 638, 640
conditional ventricular tracking limit, 644–645
piezoelectric effect, 636
piezoelectric sensors, 637–638
piezoresistive acceleration sensors, 638
redraw function, 645–646
sensors, 636, 671–672
sensors and pacemaker-mediated tachycardias, 653–656
size and function of accelerometers, 640–643
specific pacemakers, 672–674
and atrial arrhythmias, 610, 613, 615
comparison of sensors and clinical experience, **671–690**
comparative studies of sensors, 685
mixed venous oxygen saturation, 684
mixed venous pH, 684
mixed venous temperature, 679–680
paced depolarization integral, 683–684
respiration sensing (transthoracic impedance), 675–679
right ventricular pressure (first derivative), 684
sensor combinations, 685–687
stroke volume and pre-ejection interval, 685
ventricular repolarization, 680–683
vibration and body motion, 671–675
physiology of, **619–633**
atrioventricular sequential pacing, 626–627
atrioventricular synchrony, 622
biosensors, 623–624
complications and survival, 627–629
hemodynamic measurements, 619–622
rate-adaptive pacing, 622–624
ventricular pacing, 624–626
QT-sensing pacemakers, **659–660**
antitachycardia pacing, 664
bipolar endocardial T-wave sensing, 664
clinical studies, 660–661
combinations of sensors, 664–666
compared with other sensors, 662–663
future developments, 664–666
limitations of, 660–662
new developments, 663–664
QT interval as a biosensor, 659–660
smart rate-adaptive pacemakers, 585
in supraventricular tachyarrhythmias, 584–585
ventricular depolarization gradient as a sensor, 666–667
Refractory periods in pacemakers, QT-sensing pacemakers, 664
retriggerable atrial refractory period, 583–584
types of, 598–599
Respiration sensing (transthoracic impedance), in adaptive-rate pacemakers, 675–679
Resuscitation, and cardiac pacing, 567–568
hospitals as centers of, 568–569
Rheumatic tricuspid valve disease, 8–10, 49
Right coronary artery, 70
Right ventricle, anatomy and pathology, **1–21**, 70–73
pathology, 2–8
right-sided valvular heart disease, 8–17
assessment of function, **23–39**
effect of various disease processes, 29–35
functional parameters and normal values, 27–29
techniques, 23–27
ventricular interdependence, 35–37
assist devices, **185–192**
clinical applications, 188–191
mechanical interventions, 186–187
and medical therapy, 185–186
specific devices, 187–188
in congenital heart disease, **91–110**
atrial septal defect, 99–101
congenitally corrected transposition, 103–105
Eisenmenger's syndrome, 101–103
Fontan operation, 105–106
pulmonary valve stenosis, 97–99
Tetralogy of Fallot, 91–94, 157–159
transposition of great arteries, complete, 94–97
echocardiography, **41–57**
arrythmogenic dysplasia, 55
chamber volumes, 44–47
endocarditis, 53
enhanced imaging techniques, 55
ischemia, 52
masses, 53–54
normal views, 41–44
pericardial disease, 54–55
pressure overload, 51–52
valvular disease and congenital anomalies, 49–51
volume overload, 48–49
endovascular infections, **137–149**
clinical manifestations, 141–143
incidence, 139
microbiology, 141
pathogenesis, 138–139
pathology, 137–138
predisposing conditions, 139–140
prognosis, 147
treatment, 143–147
hemodynamics, **59–67**
anatomy and blood supply, 61–62
normal function, 59–61
ventricular function, assessment of, 62–64
in disease states, 64–65
infarction, **69–90**. See also *Right ventricular infarction*
nuclear imaging techniques, **23–39**
functional parameters and normal values, 27–29
right ventricular function in disease processes, 29–35
techniques, 23–27
ventricular interdependence, 35–37
in pulmonary disease, **111–135**
acute cor pulmonale, 124
alveolar hypoventilation with normal lungs, 120–122
basic physiology, 111–115
chronic obstructive pulmonary disease, 115–118
interstitial lung disease, 118–120
obliterative pulmonary vascular diseases, 122–124
therapy, 124–130
in pulmonary venous hypertension, **165–184**
etiologies, 165–166
pathophysiology, 166–170
prognosis, 178–180
response of right ventricle, 170–177
therapy, 177–178
tachycardia in, origins of, **151–164**
ischemia, 157–160
outflow tract tachycardia, 155–157
right ventricular dysplasia, 152–155

scar secondary to surgical repair of congenital disease, 157–160
Right ventricular dysplasia, 298, 312–313
Right ventricular failure, assist devices and, **185–192**
balloon counterpulsation, 187
as a bridge to transplantation, 190–191
clinical applications, 188–191
drug therapy, 185–186
pericardiotmy and atrial septostomy, 186–187
types of assist devices, 187–191
weaning from cardiopulmonary bypass devices, 188–190
Right ventricular hypertrophy, ischemia in, 6
Right ventricular infarction, anatomy and pathology, 4–6, **69–90**
complications, 79–80
in coronary heart disease, 4–6
diagnosis, 75–80
echocardiographic diagnosis, 78–79
electrocardiography, 76–77
hemodynamic findings, 79
historical overview, 69–75
interventional treatment, 83–83
ischemia and, 6
isoenzyme analysis, 77
management and therapy, 80–85
medical therapy, 80–82
myocardial scintigraphy, 78
nuclear imaging, 29–31
physical examination, 76
prognosis, 84–85
radionuclide angiocardiography, 77
surgical therapy, 83–84
thrombolytic therapy, 80–81
volume loading, 81–82
Right ventricular pressure (first derivative) sensing, in adaptive-rate pacemakers, 684
Right ventricular wall motion, nuclear imaging techniques, 27–28
Risk assessment. See also *Indications for ambulatory electrocardiography*
ambulatory monitoring for, 382–384
heart rate variability, 493–494
peripheral vascular surgery, **467–472**
ambulatory electrocardiography, 469–471
dipyridamole thallium scintigraphy, 469, 471
exercise treadmill testing, 467, 469
intraoperative and postoperative ambulatory electrocardiography, 471
multifactorial cardiac risk index, 468
preoperative ambulatory electrocardiography, 470–471
signal averaging electrocardiography, 373–374
Rohrer-Kahlstorf formula, 201
Runners. See also *Dynamic exercise*
cardiac structure in, 242–244
left ventricular mass, 284
left ventricular wall thickness, 223
maximal oxygen consumption, 284

Scintigraphy, myocardial, of right ventricular infarction, 78
Scopolamine, and heart rate variability, 491
Sensors, in adaptive-rate pacemakers. See under *Rate-responsive pacing*
Septic shock, nuclear imaging of, 33–34
Septicemia, resulting from pacemaker lead infection, 736
Septum. See *Heart septum*
Shot putters. See *Static exercise*
Sick sinus syndrome. See also *Sinus node disease*
chronotropic assessment, 712–713
pacing indications for, 583, 585
in patients with atrial arrhythmias, 611, 612
Signal averaging electrocardiography, **539–549**
applications, 355, 356, 539–544
background, 539–544
clinical utility, 546–547
evaluation of arrhythmias, 371–375
future directions, 548
history and literature, 544–547
late potential detection, 540–548
limitations, 548
risk assessment, 371–375
Silent myocardial ischemia. See *Myocardial ischemia, silent*
Single-chamber rate-modulated pacing, timing cycle, 595
Sinus node disease. See also *Sick sinus syndrome*
survival in patients with permanent pacemakers, 698–700
atrial pacing, 698
comparison of different pacing modes, 698–700
ventricular pacing, 698
survival in untreated patients, 695
Skeletal muscles, after cessation of training, 263
effect of systematic training, 216
response to static exercise, 213–214
Slow atrial rhythms, 367
Slow ventricular rhythms, 367
Spiroergometry, 201
Sprinting, 245, 247
SSIR pacing, timing cycle, 595
ST-segment changes, after percutaneous transluminal coronary angioplasty, 440–441, 483
before and after coronary artery bypass graft surgery, 432–436
conditions other than myocardial ischemia, 410
evaluation by ambulatory electrocardiography, 352–353, 553
myocardial ischemia, 403, 409–411, 422–423, 449–450
Stable angina pectoris, 405–410
Starling mechanism. See *Frank-Starling mechanism*
Static exercise, **281–294**
acute cardiovascular response to, 281–282
blood lipid, glucose, and insulin changes, 290–291
cardiac output and, 212
cardiac structure of athletes in various sports, 247, 248
cardiovascular training effects, 282–285
combined with dynamic exercise, 214–215, 222
compared with dynamic exercise, 229–230, 281–282
defined, 209
genetic factors and athlete's heart, 253–254
hemodynamic changes, caused by static exercise, 286–289
left ventricular function following, 285–286
maximal oxygen consumption and, 282
morphologic consequences of, 221, 222–223, 247
normal values for left ventricle in various sports, 269
in patients with cardiovascular disease, 289–290
peripheral cardiovascular adaptation, 286–291
physiologic response to, 212–214
skeletal muscle response to, 213–214
thickening of heart septum and wall caused by, 220
weight lifting as example of, 209
Stokes-Adams attacks, and invention of pacemaker, 563, 566, 567

Stress, as trigger of myocardial ischemia, 406–407
Stress testing. See *Exercise testing*
Stroke, prevention, by physiologic pacing, 700–701
Stroke volume. See also *Cardiac output*
  adjusted stroke work in static exercise, 288
  in athlete's heart, 204, 205–206, 295–296
  effect of upright and supine positions, 211
  Frank-Starling mechanism and, 204, 211, 258
  hemodynamic changes after cessation of training, 263–264
  in isometric exercise, 212, 287
  and pre-ejection interval sensing, in adaptive-rate pacemakers, 685
  and rate-responsive pacing, 620
  relation to oxygen consumption (VO_2), 210–211
  systematic training effect, 214, 219–220, 258
Subendocardial ischemia, and ventricular arrhythmias, 454–456
Sudden cardiac death, in athletes, causes of, 297–298, **303–317**, 320, 331
    coronary artery anomalies, 309–312
    coronary atherosclerosis, 305–306
    hypertrophic cardiomyopathy, 306–309
    idiopathic left ventricular hypertrophy, 309
    implications for cardiac screening, 315
    miscellaneous causes, 313–315
    right ventricular dysplasia, 312–313
  defined, 303
  incidence and frequency, 199, 303, 319–320
  published reports of, 304–305
  risk assessment, ambulatory monitoring, 382–384
  electrophysiologic testing, 385–388
  heart rate variability, 493–494, 517, 520–521
  and silent myocardial ischemia, **449–459**
  causal mechanisms, 450–456
  direct and indirect relationship between, 456–457
  electrical instability and ischemia, 451
  epidemiology, 450
  ischemic cascade, 450
  late proarrhythmia, 457
  physiopathology of sudden death, 452
  risk markers, 451
  severe transmural and persistent ischemia, 452–453
  subendocardial ischemia, 454–456
  triggers and markers, 452
Supraventricular tachycardia. See *Tachycardia, supraventricular*
Surveillance electrocardiography, 347–348
Survival in patients with permanent pacemakers, **691–703**
  effects of various pacing modes, 695–700
  bifascicular block, 698
  high-grade atrioventricular block, 695–698
  sinus node disease, 698–700
  improved survival using physiologic pacing modes, 700–701
  rate-responsive pacing, 627–629
  survivorship curves in different age groups, 694
  untreated conduction disturbances, 691–695
  bifascicular block, 693, 695
  complete heart block, 692–693
  sinus node disease, 695
  type I atrioventricular block, 691
  type II atrioventricular block, 691–692
Swimmers, 243, 244–245. See also *Dynamic exercise*
Sympathomimetics, for right ventricle dysfunction in pulmonary disease, 127
Syncope, pacing indications for, cough syncope, 575
  deglutition (swallowing) syncope, 575
  neurally mediated syncope, 574–575
Systematic training. See *Training, systematic*
Systolic blood pressure. See *Blood pressure*
Systolic function, assessment of, 62–63
  determinants of, 171
  of left ventricle. See under *Left ventricle*

Tachycardia, nonsustained ventricular tachyarrhythmia (NSVT), 376, 377, 382–384, 387–388
  origins of, in right ventricle, **151–164**
  ischemia, 160
  outflow tract tachycardia, 155–157
  right ventricular dysplasia, 152–155
  scar secondary to repair of congenital heart disease, 157–159
  QT-sensing pacemakers for antitachycardia pacing, 664
  sensitivity of Holter monitors, 547
  sensors for pacemaker-mediated tachycardias, 653–656
Tachycardia, supraventricular, 361–364
  accelerated atrioventricular junctional rhythm, 363–364
  atrial fibrillation, 362–363
  atrial flutter, 362
  atrial tachycardia, 361–362
  atrioventricular nodal tachycardia, 363
  circus movement tachycardia, 364, 365
  classification and mechanisms, 361–364
  long-term electrocardiographic recordings, 364–367
  pacing indications for, 583–585
  conventional pulse generators, 583–584
  rate control, 584–585
  smart rate-adaptive pacemakers, 585
Telemetry, in surveillance electrocardiography, 347–348
Tetralogy of Fallot, background, 91–92
  as cause of right ventricular tachycardia, 157–159
  diagnosis, 92
  physiology, 92
  surgical management, 92–94
Theophylline, for right ventricle dysfunction in pulmonary disease, 126–127
Throwers. See *Static exercise*
Time domain measurements of heart rate variability. See under *Heart rate variability*
Timing cycles of permanent pacemakers, **593–608**
  AAI, 594–595
  atrioventricular interval, 599–600
  base rate behavior, 601–602
  blanking period, 599–600
  cross-talk, 599
  DDD, 598
  DDDR, 603–604
  DDI, 597
  DDIR, 597
  DVI and DVIR, 595–597
  refractory periods, 598–599
  sensed events and sensor function of pacemakers, 594
  single-chamber rate-modulated pacing, 595
  upper rate behavior, 602–603
  upper rate behavior of DDDR pacemakers, 604–607
  VDD and VDDR, 597–598
  VVI, 594
Traction, for extracting pacemaker leads, 737–739
  clinical experience with countertraction, 745–746
  external traction, 737–739
  internal traction, 739

intravascular countertraction, 739–743
Training, systematic, morphologic consequences, **219–226**
changes due to training, 224
development of athlete's heart, 223–224
echocardiographic studies, 220–21
left ventricular cavity, 221
left ventricular mass, 223
left ventricular wall thickness, 221–223
physiologic versus pathologic hypertrophy, 224–225
structural alterations, 230–232
physiological consequences, **209–218**
dynamic exercise and, 209–212
effects of systematic training, 214–217
on heart rate, 215–216
on organ system other than heart, 216
serum lipids and, 216–217
skeletal muscle response and, 213–214
static exercise and, 212–214
quantification of exercise intensity, 228–229
Transplantation. See *Heart transplantation*
Transposition of great vessels, complete, 94–97
corrected, 103–105
Transtelephonic electrocardiographic devices, 345–347
Triathletes, cardiac structure in, 245, 246
Tricuspid valve, anatomy, 1
carcinoid tumors, 10–11, 49
Ebstein's anomaly, 11–14, 49
echocardiography, 49–52
endocarditis, 14–15, 53, 139, 142–143
insufficiency, 11
miscellaneous lesions, 17
prolapse, 15–17
rheumatic disease of, 8–10, 49

Uhl's anomaly, 49–50, 152, 153, 312. See also *Dysplasia, arrhythmogenic*
Unstable angina pectoris, 411, 424–425
Upper rate behavior, in pacemakers, DDDR pacemakers, 604–607
timing cycle, 602–603

Valves. See Pulmonary valve; *Tricuspid valve*
Valvular disease. See also Mitral valve stenosis; *Pulmonary valve stenosis*
echocardiography, 49–50
endocarditis, 137–138, 142–143
mitral valve disease, in rheumatic tricuspid valve disease, 10
nuclear imaging, 34
Variant angina pectoris, 410–411
Vascular surgery. See *Peripheral vascular surgery*
Vasodilators, in primary pulmonary hypertension, 128–129
for right ventricle dysfunction in pulmonary disease, 127–130
in secondary pulmonary hypertension, 129–130
Ventricle, heart. See *Left ventricle; Right ventricular dysplasia*
Ventricular arrhythmias. See *Arrhythmias*
Ventricular depolarization gradient, as a sensor for pacing, 666–667
Ventricular interdependence, nuclear imaging studies of, 35–37
Ventricular late potentials. See *Late potentials*
Ventricular pacing. See *VVD and VDDR pacing; VVI pacing; VVIR pacing*
Ventricular repolarization (stimulus to T interval sensing, in adaptive-rate pacemakers, 680–683
Ventriculoatrial conduction, retrograde, and pacemaker mode selection, 721
Ventriculotomy, for pacemaker lead extraction, 744
VEST. See *Ambulatory radionuclide left ventricular function studies*
Vibration-type pacemakers. See under *Rate-responsive pacing*
$VO_{2\,max}$. See *Maximal oxygen consumption (VO_2)*
Volume, right ventricular, echocardiographic measurement, 44–47
nuclear imaging techniques, 28–29
Volume loading, afterload, 232–233
cardiac response to, 220
as cause of physiologic hypertrophy, 231–232, 283
maximal cardiac volumes for different athletic disciplines (table), 204
preload, 233–235
Volume overload, right ventricular, hemodynamics, 64
nuclear imaging techniques, 48–49
VVD and VDDR pacing, for high-grade atrioventricular block, 696–697
timing cycle, 597–598
VVI pacing, after heart transplantation, 582
and atrial arrhythmias, 610
atrial fibrillation and, 610, 611
carotid sinus syndrome, 574
complications and survival, 628
coronary artery disease, 579–580
defined, 594
for high-grade atrioventricular block, 695–696
neurally-mediated syncope, 574
rate-responsive pacing, 624–626
sinus node disease, 698–700
VVIR pacing, compared with DDD pacing, in rate-responsive pacing, 626–627
coronary artery disease, 579–580
for high-grade atrioventricular block, 697–698
rate-responsive pacing, 625–626
timing cycle, 595, 596

Wall motion, right ventricular, nuclear imaging techniques, 27–28
Weight lifters. See *Power athletes*
Women, maximal oxygen consumption after puberty, 210
physiologic hypertrophy in, compared with men, 201, 269
in older women, 259
sudden death not reported in young women athletes, 320
Wrestlers. See *Power athletes*

Zoll, Paul M., and invention of pacemaker, 561, 565–566